Compare APC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | CSTL |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.3M | 722.8M |
| IPO Year | N/A | 2019 |
| Metric | APC | CSTL |
|---|---|---|
| Price | $20.30 | $28.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $21.75 | ★ $45.50 |
| AVG Volume (30 Days) | 84.9K | ★ 290.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $4.47 | $2.42 |
| Revenue Next Year | $4.20 | $12.69 |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $17.08 | $14.59 |
| 52 Week High | $21.72 | $44.28 |
| Indicator | APC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 75.45 |
| Support Level | $17.55 | $22.67 |
| Resistance Level | $21.48 | $34.97 |
| Average True Range (ATR) | 0.75 | 1.31 |
| MACD | -0.06 | 0.33 |
| Stochastic Oscillator | 20.78 | 84.88 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.